Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
30.43
-2.71 (-8.18%)
At close: Feb 21, 2025, 4:00 PM
31.00
+0.57 (1.87%)
After-hours: Feb 21, 2025, 6:57 PM EST
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Beam Therapeutics stock have an average target of 48.75, with a low estimate of 24 and a high estimate of 80. The average target predicts an increase of 60.20% from the current stock price of 30.43.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Beam Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 5 | 5 | 5 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +162.90% | Feb 3, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Jan 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +162.90% | Dec 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +162.90% | Nov 7, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $27 → $24 | Hold | Maintains | $27 → $24 | -21.13% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
52.45M
from 377.71M
Decreased by -86.11%
Revenue Next Year
60.12M
from 52.45M
Increased by 14.62%
EPS This Year
-4.77
from -1.72
EPS Next Year
-4.86
from -4.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 78.8M | 115.5M | 168.0M | |||
| Avg | 52.4M | 60.1M | 65.1M | |||
| Low | 37.2M | 25.5M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -79.2% | 120.2% | 179.5% | |||
| Avg | -86.1% | 14.6% | 8.3% | |||
| Low | -90.1% | -51.4% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.58 | -3.51 | -2.61 | |||
| Avg | -4.77 | -4.86 | -4.48 | |||
| Low | -4.93 | -5.76 | -5.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.